Study analysis · Current Obesity Reports · 2026
Why your diet fails: your body has a secret hunger switch that got stuck on 'off'
When you lose weight, your body lowers your hunger hormone and raises a 'stop eating' hormone, making you feel less hungry even when you need to eat — and that’s why most diets fail.
Overview
What the study found
The study in plain English — the bottom line, every takeaway we extracted, and what to do with them.
In simple terms
This study is like a big summary of lots of other science stories — some from mice, some from test tubes, and a few from people. It says 'maybe this hormone does this' or 'it looks like these two things happen together,' but it doesn't prove that one causes the other. It's telling us what scientists think might be going on, not what they know for sure.
What’s the bottom line?
Your body has two hormones that control hunger: ghrelin says 'eat!' and LEAP2 says 'stop eating.' When you're hungry, ghrelin goes up and LEAP2 goes down. When you eat, it flips. But in people with obesity, ghrelin is too low and LEAP2 is too high, so the body doesn't feel hungry even when it needs food — making diets hard to stick to.
How strong is this study?
This isn't a well-designed experiment — it's more like a teacher writing a report using notes from different students' projects. Some notes might be good, some might be shaky, and we don't know if the teacher picked the best ones. That means we can't fully trust the conclusions unless someone does a real, careful study to check them.
0 / 100
- COI disclosureconflicts of interest not disclosed
- Data availabilitydata not shared
- Code availabilitycode not shared
0 / 100
- Randomizationrandomization unclear
- Blindingblinding unclear
- Control groupno control group
- Sample sizeno sample size reported
- Follow-upno follow-up reported
100 / 100
0 / 100
- P-valuesno p-values reported
- Effect sizeno effect size reported
- Confidence intervalsno confidence intervals
- Pre-registrationnot pre-registered
Each component is scored out of 100 and then capped by the study design — a case series cannot reach the ceiling a randomised trial can, however well it is reported.
Where it sits
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 51 / 100
Probability of being correct
Systematic reviews and meta-analyses of cohort studies. They sit above a single cohort study but below a single randomized trial, because the underlying evidence is still observational.
This design cannot establish causation — the findings describe an association, not a cause. This is a narrative review that synthesizes findings from mixed primary studies (including animal, in vitro, and human observational studies), but does not include original data, randomization, control groups, or statistical analysis to establish cause-effect relationships. It presents hypotheses and associations based on existing literature without rigorous evidence synthesis.
No Conflicts
No conflicts of interest identified
No conflicts of interest or funding statements were disclosed in the text; the review appears to be an independent synthesis of existing scientific literature.
The text is a review article summarizing existing research on the ghrelin-LEAP2 system with no mention of authors' affiliations, funding sources, or competing interests. No industry involvement or bias indicators are present.
Key takeaways
- 01
LEAP2 reduces food intake and lowers blood sugar after meals as much as GLP-1 (a known weight-loss drug target).
- 02
In obesity, ghrelin is lower than expected, and LEAP2 is higher, weakening the hunger signal.
- 03
This means your body's natural hunger signal gets muted after weight loss, making it easier to regain weight — explaining why most diets fail long-term.
Surprising findings
- LEAP2 reduces blood sugar and appetite as effectively as GLP-1 — a major drug target — but without causing nausea.GLP-1 drugs like Ozempic are famous for their power but notorious for side effects. Finding a natural hormone that matches their effect without the nausea flips the script on what’s possible.
- People with anorexia nervosa have sky-high ghrelin levels — but still can’t eat. Their brains are 'ghrelin resistant.'You’d think high hunger hormone = huge appetite. But in anorexia, the brain ignores it — proving hunger signals can be broken, not just low.
Practical takeaways
If you’ve lost weight and are struggling to keep it off, understand it’s not your fault — your hormones are working against you. Consider talking to a doctor about GLP-1 or future LEAP2-based therapies.
LEAP2 therapies aren’t available yet — this is still in early human trials. Don’t expect a pill tomorrow.
medium confidenceAvoid extreme calorie restriction if you’ve had weight loss before — it worsens the ghrelin/LEAP2 imbalance and makes rebound weight gain more likely.
This doesn’t mean don’t diet — it means avoid yo-yoing. Focus on sustainable, moderate changes.
high confidenceTrack your hunger cues after meals — if you feel unusually flat or numb, it might be your LEAP2 levels rising, not your willpower failing.
Hunger is complex — stress, sleep, and emotions also play big roles. Don’t blame LEAP2 for everything.
low confidenceWhy this study matters
The Hunger Hormone Duo
Ghrelin tells you to eat, and LEAP2 tells you to stop. In healthy people, ghrelin rises before meals and LEAP2 rises after. But in obesity, ghrelin drops and LEAP2 spikes — flipping the ratio so your body thinks it’s full even when it’s starving.
This explains why you feel less hungry after losing weight — not because you’re weak, but because your biology is working against you.
LEAP2 Works Like GLP-1 (But Without the Nausea)
Infusing LEAP2 into obese men reduced food intake and post-meal blood sugar as much as GLP-1 — the active ingredient in weight-loss drugs like Ozempic — but without causing nausea or stomach upset.
This could mean a new weight-loss drug that works as well as Ozempic but with fewer side effects — and it’s already been tested in humans.
Your Body Thinks You’re Starving — Even When You’re Not
People with obesity have a blunted ghrelin/LEAP2 ratio — meaning their hunger signal is muted. This isn’t just about willpower; it’s a biological adaptation that makes weight regain almost inevitable.
This turns the blame game upside down: it’s not that you ‘can’t stick to a diet’ — your hormones are actively sabotaging you.
Want the whole report?
Detailed mode opens the full scientific breakdown — every score component, the methodology, conflicts of interest, the evidence analysis behind each claim, and the raw study data.
Overview
What the study found
The study in plain English — the bottom line, every takeaway we extracted, and what to do with them.
Not medical advice. For informational purposes only. Always consult a healthcare professional. Terms
Your body has two hormones that control hunger: ghrelin says 'eat!' and LEAP2 says 'stop eating.' When you're hungry, ghrelin goes up and LEAP2 goes down. When you eat, it flips. But in people with obesity, ghrelin is too low and LEAP2 is too high, so the body doesn't feel hungry even when it needs food — making diets hard to stick to.
Research results
LEAP2 reduces food intake and lowers blood sugar after meals as much as GLP-1 (a known weight-loss drug target). In obesity, ghrelin is lower than expected, and LEAP2 is higher, weakening the hunger signal.
What this means - more context
This means your body's natural hunger signal gets muted after weight loss, making it easier to regain weight — explaining why most diets fail long-term.
This narrative review examines the physiological and pathophysiological roles of the ghrelin-LEAP2 system in regulating appetite, energy balance, and glucose homeostasis, with emphasis on its relevance to obesity and type 2 diabetes.
The ghrelin-LEAP2 system functions as a dynamic rheostat for energy balance: ghrelin promotes hunger and glucose elevation, while LEAP2 antagonizes ghrelin, suppresses appetite, and lowers glucose. Obesity and type 2 diabetes are associated with reduced ghrelin and elevated LEAP2, leading to a blunted ghrelin/LEAP2 ratio that impairs adaptive hunger signaling and contributes to weight regain. LEAP2 administration reduces food intake and postprandial glucose to levels comparable to GLP-1, suggesting therapeutic potential.
Methods Used
This is a narrative review synthesizing evidence from human clinical studies, preclinical models (rodents), in vitro experiments, and observational data on circulating ghrelin and LEAP2 levels across metabolic states. No new experimental data were generated.
Main Finding
The ghrelin/LEAP2 ratio dynamically regulates energy balance and glucose homeostasis; its reduction in obesity impairs adaptive hunger responses during caloric restriction, and LEAP2 administration reduces food intake and postprandial glucose to a degree comparable to GLP-1.
Confidence Level
Moderate
Study Flags
Red Flags
- •Narrative review without systematic methodology or meta-analysis
- •Relies on correlational human data and preclinical models without clinical trial evidence for therapeutic efficacy
- •Therapeutic claims (e.g., LEAP2 analogues) are speculative and not yet validated in humans
Surprising Findings
LEAP2 reduces blood sugar and appetite as effectively as GLP-1 — a major drug target — but without causing nausea.
GLP-1 drugs like Ozempic are famous for their power but notorious for side effects. Finding a natural hormone that matches their effect without the nausea flips the script on what’s possible.
Practical Takeaways
If you’ve lost weight and are struggling to keep it off, understand it’s not your fault — your hormones are working against you. Consider talking to a doctor about GLP-1 or future LEAP2-based therapies.
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 51 / 100
Probability of being correct
Systematic reviews and meta-analyses of cohort studies. They sit above a single cohort study but below a single randomized trial, because the underlying evidence is still observational.
Narrative Review
Subject
Lower probability
on the GRADE evidence scale
This study is like a big summary of lots of other science stories — some from mice, some from test tubes, and a few from people. It says 'maybe this hormone does this' or 'it looks like these two things happen together,' but it doesn't prove that one causes the other. It's telling us what scientists think might be going on, not what they know for sure.
No conflicts of interest were detected in this study. No score impact.
Strengths
- Comprehensive synthesis of current literature on ghrelin and LEAP2
- Clear organization of complex physiological mechanisms
- Integration of findings across animal, cellular, and human studies
Weaknesses
- No systematic search strategy or inclusion/exclusion criteria reported
- No assessment of study quality or risk of bias in included primary studies
- No statistical synthesis or meta-analysis of effect sizes
Methodology
Evidence Keywords
Statistical Reporting
Not medical advice. For informational purposes only. Always consult a healthcare professional. Terms
Your body has two hormones that control hunger: ghrelin says 'eat!' and LEAP2 says 'stop eating.' When you're hungry, ghrelin goes up and LEAP2 goes down. When you eat, it flips. But in people with obesity, ghrelin is too low and LEAP2 is too high, so the body doesn't feel hungry even when it needs food — making diets hard to stick to.
Research results
LEAP2 reduces food intake and lowers blood sugar after meals as much as GLP-1 (a known weight-loss drug target). In obesity, ghrelin is lower than expected, and LEAP2 is higher, weakening the hunger signal.
What this means - more context
This means your body's natural hunger signal gets muted after weight loss, making it easier to regain weight — explaining why most diets fail long-term.
This narrative review examines the physiological and pathophysiological roles of the ghrelin-LEAP2 system in regulating appetite, energy balance, and glucose homeostasis, with emphasis on its relevance to obesity and type 2 diabetes.
The ghrelin-LEAP2 system functions as a dynamic rheostat for energy balance: ghrelin promotes hunger and glucose elevation, while LEAP2 antagonizes ghrelin, suppresses appetite, and lowers glucose. Obesity and type 2 diabetes are associated with reduced ghrelin and elevated LEAP2, leading to a blunted ghrelin/LEAP2 ratio that impairs adaptive hunger signaling and contributes to weight regain. LEAP2 administration reduces food intake and postprandial glucose to levels comparable to GLP-1, suggesting therapeutic potential.
Methods Used
This is a narrative review synthesizing evidence from human clinical studies, preclinical models (rodents), in vitro experiments, and observational data on circulating ghrelin and LEAP2 levels across metabolic states. No new experimental data were generated.
Main Finding
The ghrelin/LEAP2 ratio dynamically regulates energy balance and glucose homeostasis; its reduction in obesity impairs adaptive hunger responses during caloric restriction, and LEAP2 administration reduces food intake and postprandial glucose to a degree comparable to GLP-1.
Confidence Level
Moderate
Study Flags
Red Flags
- •Narrative review without systematic methodology or meta-analysis
- •Relies on correlational human data and preclinical models without clinical trial evidence for therapeutic efficacy
- •Therapeutic claims (e.g., LEAP2 analogues) are speculative and not yet validated in humans
Surprising Findings
LEAP2 reduces blood sugar and appetite as effectively as GLP-1 — a major drug target — but without causing nausea.
GLP-1 drugs like Ozempic are famous for their power but notorious for side effects. Finding a natural hormone that matches their effect without the nausea flips the script on what’s possible.
Practical Takeaways
If you’ve lost weight and are struggling to keep it off, understand it’s not your fault — your hormones are working against you. Consider talking to a doctor about GLP-1 or future LEAP2-based therapies.
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 51 / 100
Probability of being correct
Systematic reviews and meta-analyses of cohort studies. They sit above a single cohort study but below a single randomized trial, because the underlying evidence is still observational.
Narrative Review
Subject
Lower probability
on the GRADE evidence scale
This study is like a big summary of lots of other science stories — some from mice, some from test tubes, and a few from people. It says 'maybe this hormone does this' or 'it looks like these two things happen together,' but it doesn't prove that one causes the other. It's telling us what scientists think might be going on, not what they know for sure.
No conflicts of interest were detected in this study. No score impact.
Strengths
- Comprehensive synthesis of current literature on ghrelin and LEAP2
- Clear organization of complex physiological mechanisms
- Integration of findings across animal, cellular, and human studies
Weaknesses
- No systematic search strategy or inclusion/exclusion criteria reported
- No assessment of study quality or risk of bias in included primary studies
- No statistical synthesis or meta-analysis of effect sizes
Methodology
Evidence Keywords
Statistical Reporting
Scoring
How strong is this study?
This isn't a well-designed experiment — it's more like a teacher writing a report using notes from different students' projects. Some notes might be good, some might be shaky, and we don't know if the teacher picked the best ones. That means we can't fully trust the conclusions unless someone does a real, careful study to check them.
0 / 100
- COI disclosureconflicts of interest not disclosed
- Data availabilitydata not shared
- Code availabilitycode not shared
0 / 100
- Randomizationrandomization unclear
- Blindingblinding unclear
- Control groupno control group
- Sample sizeno sample size reported
- Follow-upno follow-up reported
100 / 100
0 / 100
- P-valuesno p-values reported
- Effect sizeno effect size reported
- Confidence intervalsno confidence intervals
- Pre-registrationnot pre-registered
Each component is scored out of 100 and then capped by the study design — a case series cannot reach the ceiling a randomised trial can, however well it is reported.
Where it sits
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 51 / 100
Probability of being correct
Systematic reviews and meta-analyses of cohort studies. They sit above a single cohort study but below a single randomized trial, because the underlying evidence is still observational.
This design cannot establish causation — the findings describe an association, not a cause. This is a narrative review that synthesizes findings from mixed primary studies (including animal, in vitro, and human observational studies), but does not include original data, randomization, control groups, or statistical analysis to establish cause-effect relationships. It presents hypotheses and associations based on existing literature without rigorous evidence synthesis.
No Conflicts
No conflicts of interest identified
No conflicts of interest or funding statements were disclosed in the text; the review appears to be an independent synthesis of existing scientific literature.
The text is a review article summarizing existing research on the ghrelin-LEAP2 system with no mention of authors' affiliations, funding sources, or competing interests. No industry involvement or bias indicators are present.
Standing
Who’s using this study?
The videos and claims on this site that lean on this study, and the researchers who wrote it.
1 video from Big Think Clips cite this study, drawing 1 claim from it.
- Correlational evidence
The evidence shows a real association, but the studies are observational, so they cannot prove cause and effect. Stronger studies could still change the picture.
Evidence
Authored by
3 researchersIf this is your work, this is how we attribute it on Fit Body Science. Isabela Valdés Calero is listed as the lead author.